Mineralys Therapeutics, Inc. (MLYS)
2025-06-30 | ||||
|---|---|---|---|---|
| Research and development | 38,278 | |||
| General and administrative | 8,468 | |||
| Total operating expenses | 46,746 | |||
| Loss from operations | -46,746 | |||
| Other income (expense) | -2 | |||
| Interest income, net | 3,474 | |||
| Total other income, net | 3,472 | |||
| Net loss | -43,274 | |||
| Net loss per share attributable to common stockholders - basic (in usd per share) | -0.66 | |||
| Net loss per share attributable to common stockholders - diluted (in usd per share) | -0.66 | |||
| Weighted-average shares used to compute net loss per share attributable to common stockholders - basic (in shares) | 65,451,297 | |||
| Weighted-average shares used to compute net loss per share attributable to common stockholders - diluted (in shares) | 65,451,297 | |||